

TABLE OF CONTENTS

	Page
Acknowledgement	iii
Abstract (English)	v
Abstract (Thai)	vii
Table of Contents	ix
List of Tables	xiv
List of Figures	xv
List of Schemes	xviii
Abbreviations and Symbols	xx
 CHAPTER I INTRODUCTION	
1.1 Statement of the problem	1
1.1.1. Malaria	1
1.1.2. Cancers	2
1.2 Research Objectives	5
1.3 Usefulness of the research	5
1.4 Scope of the study	5
 CHAPTER II LITERATURE REVIEWS	
2.1 General knowledge about malaria	6
2.2 Life Cycle of the Malaria Parasites	7
2.3 Treatment of malaria	9
2.3.1 Quinine and related compound	9
2.3.2 Antifolate combination drugs	11

2.3.3	Artemisinin compounds and its derivatives	13
2.4	Artemisinin	13
2.5	Mechanism of action of artemisinin	15
2.6	Artemisinin and its derivatives as antimalarial agents	17
2.7	General knowledge about cancer	21
2.8	Treatment of cancer	22
2.9	Artemisinin and its derivatives as anticancer agents	23
2.10	Peptide Nucleic Acid	34
2.11	Other oligopeptides and their biological activities	38

CHAPTER III EXPERIMENT

3.1	Chemicals	43
3.1.1	Chemicals for organic synthesis	43
3.1.2	Chemicals for biological testing	44
3.1.3	Cell lines	45
3.2	Modification of artemisinin derivatives at C-10	45
3.2.1	Preparation of Dihydroartemisinin 10 α -Benzoate	45
3.2.2	Preparation of 10 β -Allyldeoxoartemisinin	47
3.2.3	Preparation of 10 β -Carboxylalkyldeoxoartemisinin	48
3.3	Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu oligomers	49
3.3.1	Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu monomer	49
3.3.2	Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu dimer	51
3.3.3	Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu trimer	54
3.3.4	Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu tetramer	57

3.4	Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu oligomers	60
3.4.1	Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu monomer	60
3.4.2	Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu dimer	63
3.4.3	Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu trimer	65
3.4.4	Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu tetramer	68
3.5	Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu oligomers	71
3.5.1	Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu monomer	71
3.5.2	Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu dimer	72
3.5.3	Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu trimer	74
3.5.4	Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu tetramer	75
3.6	lys-aeg-deoxoartemisinin- <i>t</i> Bu oligomers.	76
3.6.1	lys-aeg-deoxoartemisinin- <i>t</i> Bu monomer	76
3.6.2	lys-aeg-deoxoartemisinin- <i>t</i> Bu dimer	78
3.7	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH oligomers	80
3.7.1	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH dimer	80
3.7.2	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH trimer	82
3.7.3	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH tetramer	86
3.8	Bioactivity study	90
3.8.1	Antimalarial activity	90
3.8.2	Anticancer activity	91

CHAPTER IV RESULTS & DISCUSSION

4.1	Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu oligomers	94
4.1.1	Preparation of 10 β -Carboxylalkyldeoxoartemisinin	96
4.1.2	Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu monomer	99
4.2	Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu oligomers	100
4.2.1	Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu dimer	101
4.2.2	Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu trimer	102
4.2.3	Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu tetramer	103
4.3	Synthesis of Lysine-aeg-deoxoartemisinin- <i>t</i> Bu oligomers	104
4.3.1	Synthesis of Fmoc-lys(Boc)- aeg-deoxoartemisinin- <i>t</i> Bu monomer	105
4.3.1.1	Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu monomer	106
4.3.1.2	Synthesis of lys-aeg-deoxoartemisinin- <i>t</i> Bu monomer	108
4.3.2	Synthesis of Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu dimer	109
4.3.2.1	Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu dimer	110
4.3.2.2	Synthesis of lys-aeg-deoxoartemisinin- <i>t</i> Bu dimer	112
4.3.3	Synthesis of Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu trimer	114
4.3.3.1	Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu trimer	115
4.3.4	Synthesis of Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu tetramer	116

4.3.4.1	Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu tetramer	118
4.4	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH oligomers	119
4.4.1	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH dimer	121
4.4.2	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH trimer	122
4.4.3	Cyclization of NH ₂ -aeg-deoxoartemisinin-OH tetramer	123
4.5	Antimalarial Assessment of new deoxoartemisinin derivatives	124
4.6	Anticancer activities	126
4.6.1	The cytotoxicity against normal cell line (L929)	128
4.6.2	The cytotoxicity against colon cancer cell line (HT-29)	131
4.6.3	The cytotoxicity against colon cancer cell line (Caco-2)	136
4.6.4	The cytotoxicity against lung cancer cell line (A549)	140
4.6.5	The cytotoxicity against skin cancer cell line (B16F10)	144
	CHARPTER V Conclusion	148
	REFERENCE	152
	APPENDICES	160
	APPENDIX I STRUCTURE	161
	APPENDIX II MASS SPECTRA	167
	APPENDIX III IR SPECTRA	186
	APPENDIX IV NMR SPECTRA	205
	CURRICULUM VITAE	219

LIST OF TABLES

TABLES	Page
2.1 Antisense activities of PNA containing Lys.	37
4.1 <i>In vitro</i> antimalarial activity of all compounds against K1 strains of <i>Plasmodium falciparum</i> .	125
4.2 <i>In vitro</i> anticancer activity of deoxoartemisinin derivatives against L929 cell line.	127
4.3 <i>In vitro</i> anticancer activity of deoxoartemisinin derivatives against HT-29 cell line.	130
4.4 <i>In vitro</i> anticancer activity of deoxoartemisinin derivatives against Caco-2 cell line.	135
4.5 <i>In vitro</i> anticancer activity of deoxoartemisinin derivatives against A549 cell line.	139
4.6 <i>In vitro</i> anticancer activity of deoxoartemisinin derivatives against B16F10 cell line.	143
4.7 Summary table of cytotoxicity values of deoxoartemisinin derivatives toward various cancer cell line.	147

LIST OF FIGURES

FIGURES	Page
1.1 Chemical structure of antimalarial drugs : quinine (1), chloroquine (2), pyrimathamine (3) and mefloquine (4).	1
1.2 Chemical structure of anticancer drugs.	3
1.3 Chemical structure of quinghaosu (QHS, artemisinin).	4
2.1 Female Anopheles mosquito (<i>Anopheles ssp.</i>).	7
2.2 Life cycle of the Malaria parasites.	8
2.3 Structure of Chloroquine, Mefloquine and Primaquine.	9
2.4 Mode of action of chloroquine.	10
2.5 The structure of anti-malarial drugs.	12
2.6 The structure of artemisinin derivatives.	15
2.7 Propose mechanism of action of artemisinins.	17
2.8 Structure of acetal and non acetal (C-C) type prodrugs of artemisinin.	18
2.9 Structure of artemisinin water soluble derivatives.	19
2.10 Structure of (+)-deoxyartemisitenone (34), artemisinic acid (35) and its novel C-11 derivatives with non-acetal at C-12 (36-39).	20
2.11 Chemical structure of deoxyartelinic acid (40).	21
2.12 Cells divide and grow uncontrollably, forming malignant tumors.	22
2.13 Chemical structure of artemisinin-related analogs 41a,b, 42 and 43.	24

2.14	Chemical structure of dihydroartemisinin containing cyano and aryl group.	25
2.15	Artemisinin derivatives with amide bearing linear alkyl carbon chains.	26
2.16	Structure of artemisinin and selected derivatives.	27
2.17	C-16 derived artemisinin monomers, dimers, trimers and tetramers.	28
2.18	C-10 non-acetal type derivatives of deoxyartemisinin as monomers (65), (66), dimers (67 , 68a,b) and one trimer (69).	29
2.19	A new series of non-acetal C-10 carba trioxane analogues of dimers (70a-70c , 71a , 71b , 72a-72c , 73a , 73b).	30
2.20	The new series of hydrolytically stable, C-10 non acetal dimer (74-79).	31
2.21	The C-10 carba artemisinin dimers with amide (80), carbonate (81a), urea (81b) and 4,4'- bipiperidine-linker (82) and phosphonate-linked dimer (83).	32
2.22	N^1 -, N^4 - and N^8 - artemisinin-spermidine conjugated 84-89	33
2.23	Comparison structure of PNA and DNA.	35
2.24	Synthetic pathway of Fmoc-Py- <i>t</i> Bu (92), Fmoc-Ac- <i>t</i> Bu (91) and bisintercalator 94 .	35

2.25	(a) Effect of the number of N-terminal lysine residues on the reduction of CD40 expression in mouse BCL1 cells.	36
	(b) Effect of both C and N terminally conjugated <i>L</i> -lysine peptides on the inhibition of CD40 expression.	
2.26	Structure of Fmoc-amino acid amides.	39
2.27	Structure of Fmoc-acetate dipeptides (117-119), Fmoc-alcohol dipeptides (114-116) and Fmoc-benzoate dipeptides (120-123).	40
2.28	Chemical structures of cyclo (Phe-Pro) (124).	41
4.1	LD ₅₀ values of monomer (132, 141, 148) and dimer (134, 143, 149) compound against normal cancer cell.	129
4.2	Comparison of the cytotoxicities of monomer (132, 141, 148, 152) and dimer (134, 143, 149, 154) tested on HT-29 cancer cell.	132
4.3	Comparison of the cytotoxicities of Fmoc-lys-aeg-artemisinin- <i>t</i> Bu oligomers tested on HT-29 cancer cell.	133
4.4	Comparison of the cytotoxicities of monomer series and dimer series tested on Caco-2 cancer cell.	137
4.5	Comparison of the cytotoxicities of monomer 132, 141, 148, 152 dimer 134, 143, 149, 154 tested on A549 cancer cell.	141
4.6	Comparison of the cytotoxicities of monomer series 132,141 and 148 and dimer series 134, 143 and 148 tested on B16F10 cancer cell.	145

LIST OF SCHEMES

SCHEMES	Page
4.1 Retrosynthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu oligomers.	95
4.2 Synthesis of dihydroartemisinin 10 α -benzoate. (129)	96
4.3 Synthesis of 10 β -allyldeoxoartemisinin. (130)	97
4.4 Synthesis of 10 β -carboxylalkyldeoxoartemisinin. (131)	98
4.5 Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu monomer. (132)	99
4.6 Synthesis pathway of peptide synthesis	100
4.7 Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu dimer. (134)	101
4.8 Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu trimer. (137)	102
4.9 Synthesis of Fmoc-aeg-deoxoartemisinin- <i>t</i> Bu tetramer. (139)	103
4.10 Synthesis of Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu monomer. (141)	105
4.11 Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu monomer. (148)	106
4.12 Synthesis of lys-aeg-deoxoartemisinin- <i>t</i> Bu monomer. (152)	108
4.13 Synthesis of Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu dimer. (143)	109
4.14 Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu dimer. (149)	110
4.15 Synthesis of lys-aeg-deoxoartemisinin- <i>t</i> Bu dimer. (154)	112
4.15 (continued) Synthesis of lys-aeg-deoxoartemisinin- <i>t</i> Bu dimer. (154)	113

4.16	Synthesis of Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu trimer. (144)	114
4.17	Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu trimer. (150)	115
4.18	Synthesis of Fmoc-lys(Boc)-aeg-deoxoartemisinin- <i>t</i> Bu tetramer. (146)	116
4.19	Synthesis of Fmoc-lys-aeg-deoxoartemisinin- <i>t</i> Bu tetramer. (151)	118
4.20	Retrosynthesis of cyclic-aeg-deoxoartemisinin-oligomers.	120
4.21	Synthesis of cyclic-aeg-deoxoartemisinin-dimer. (156)	121
4.22	Synthesis of cyclic-aeg-deoxoartemisinin-trimer. (158)	122
4.23	Synthesis of cyclic-aeg-deoxoartemisinin-tetramer. (161)	123

ABBREVIATIONS AND SYMBOLS

g	gram
mmol	millimole
ml	milliliter
mg	milligram
h	hours
min	minute (s)
%	percent
Mp	melting point
°C	degree celcius
cm ⁻¹	wave number
m/z	mass to charge ratio
FT-IR	Fourier Transform Infrared
HRMS	High Resolution Mass Spectrometry
LRMS	Low Resolution Mass Spectrometry
ESI	Electrospray Ionization
¹ H-NMR	Proton Nuclear Magnetic Resonance
¹³ C NMR	Carbon-13 Nuclear Magnetic Resonance
MHz	Megahertz
ppm	part per million
Hz	Hertz
δ	chemical shift (ppm)
α	alpha
β	beta

<i>J</i>	coupling constant (NMR signal)
d	doublet (NMR signal)
s	singlet (NMR signal)
t	triplet (NMR signal)
q	quartet (NMR signal)
td	triplet of doublet (NMR signal)
m	multiplet (NMR signal)
RP-HPLC	Reverse-Phase High Performance Liquid Chromatography
mM	millimolar
μl	microliter
% v/v	percent volume by volume (concentration)
μg	microgram
rpm	revolutions per minute
μM	micromolar
nM	nanomolar
IC ₅₀	inhibition concentration (50%)
LD ₅₀	lethal dose (50%)
aeg	<i>N</i> -(2-aminoethyl)glycine
Fmoc	Fluorenylmethyloxycarbonyl
Boc	<i>tert</i> -Butyloxycarbonyl group
DIEA	<i>N,N</i> -Diisopropylethylamine
Lys	Lysine
Phe	Phenylalanine
Pro	Proline

PNA	Peptide Nucleic Acid
DCE	Dichloroethane
TFA	Trifluoroacetic acid
DMF	<i>N,N</i> -Dimethylformamide
HATU	2-(1 <i>H</i> -7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium
2,6-Lutidine	2,6-Dimethylpyridine
NaHCO ₃	Sodium hydrogen carbonate
MgSO ₄	Magnesium sulphate anhydrous
ZnCl ₂	Zinc chloride
NaIO ₄	Sodium periodate
KMnO ₄	Potassium permanganate
HCl	Hydrochloric acid
CH ₂ Cl ₂	Dichloromethane
NaCl	Sodium Chloride
HOAt	1-Hydroxy-7-azabenzotriazole
KCl	Potassium chloride
Na ₂ HPO ₄	Sodium dihydrogen phosphate
KH ₂ PO ₄	Potassium dihydrogen phosphate
FBS	Foetal bovine serum
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide